Dengue Fever Clinical Trial
Official title:
Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children
The purpose of this study is to evaluate the safety and effectiveness of two different formulations of an investigational dengue vaccine (T-DEN) against a placebo vaccine when two doses are given six months apart to adults and children.
Status | Completed |
Enrollment | 636 |
Est. completion date | April 2010 |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 12 Months to 50 Years |
Eligibility |
Inclusion Criteria: - Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study. - A healthy male or non-pregnant female between 12 months (mths) and 50 years (yrs) of age at the time of the first vaccination; - Free of obvious health problems as established by medical history and physical examination before entering into the study; - For children: 23mths of age, full compliance with the United States Advisory Committee on Immunization Practices (U.S. ACIP) recommended childhood immunization schedule; - Written informed consent obtained from the subject or a parent/guardian and assent for subjects 7-20 yrs of age; - If the subject is female, she must be of non-childbearing potential, i.e. either pre-menarcheal, surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (i.e. intrauterine contraceptive device; condom and spermicide combination, oral contraceptives or other equivalent hormonal contraception, e.g. progestin implantable, cutaneous hormonal patch or injectable contraceptives) for 30 days (dys) prior to vaccination, have a negative pregnancy test within 48 hrs prior to vaccination and must agree to continue such precautions for 60 dys after completion of the vaccination series. Any child who begins menarche during the study period must follow the same precautions listed above, from menarche until 60 dys after the second vaccine dose. Exclusion Criteria: - Pregnant or lactating female; - Female planning to become pregnant or planning to discontinue abstinence or contraceptive precautions; - History of any neurological or behavioral disorder or seizures, with the exception of a single febrile seizure in childhood; - History of allergic disease/reaction likely to be exacerbated by any component of the vaccine; - Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal, hematologic or endocrine functional defect, as determined by physical examination or laboratory tests; - Any confirmed or suspected immunosuppressive or immunodeficient condition; - Acute disease at the time of enrollment (acute disease is defined as the presence of a moderate or severe illness with or without fever); note that vaccine can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., equivalent to an oral temperature <37.5°C/<99.5°F. - Chronic hepatomegaly, right upper quadrant abdominal pain or tenderness; - Chronic splenomegaly, left upper quadrant abdominal pain or tenderness; - Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 dys preceding the first dose of study vaccine/placebo or planned use during the study period; - Planned administration of a vaccine not foreseen by the study protocol during the period starting from 30 dys before each dose of the study vaccine and ending 30 dys after; with the exception of standard infant and children "inactivated" vaccines or the inactivated influenza vaccine administered to adults or children; - A planned move to a location that will prohibit participating in the trial for the 12 mth duration; - Chronic administration (defined as more than 14 dys) of immunosuppressants or other immune-modifying drugs within 90 dys preceding the first dose or planned administration during the study period. For corticosteroids, this will mean prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed; - Administration of immunoglobulins and/or blood products within 90 dys preceding the first dose or planned administration during the study period; - Hypertension; - Chest pain, palpitations, dizziness, shortness of breath unrelated to asthma, arrhythmias or friction rubs; - Any chronic systemic drug therapy to be continued during the study period (except for vitamin/mineral supplements, routine treatment for gastro-esophageal reflux); - Potential adult volunteers, or parents of potential child volunteers, who do not have easy access to a fixed or mobile telephone; - History of chronic alcohol consumption and/or drug abuse. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Puerto Rico | San Juan Batista Medical School | Caguas | |
Puerto Rico | Private Practice | Carolina | |
Puerto Rico | St Luke's Memorial Hospital | Ponce | |
Puerto Rico | Caparra Internal Medicine Research Center | Rio Grande | |
Puerto Rico | Private Practice | Rio Piedras | |
Puerto Rico | RCMI Clinical Research Center | Rio Piedras | |
Puerto Rico | Torre Medica San Vicente de Paul | San German | |
Puerto Rico | Centro de Neumologia Pediatricia | San Juan | |
Puerto Rico | Clinical Research PR | San Juan | |
Puerto Rico | Dept Pediatria, Esc. De Medicina | San Juan | |
Puerto Rico | Private Practice | San Juan |
Lead Sponsor | Collaborator |
---|---|
U.S. Army Medical Research and Materiel Command | GlaxoSmithKline |
Puerto Rico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence, intensity and relationship to vaccination of any solicited local and general adverse events | Within 21 days (days 0-20) f/up period after each vaccine dose | Yes | |
Primary | Occurrence, intensity and relationship to vaccination of each type of solicited local and general adverse events | Within the 21-day (days 0-20) follow-up period after each vaccine dose | Yes | |
Primary | Occurrence, intensity and relationship to vaccination of unsolicited AEs | Within the 31-day (days 0-30) follow-up period after each vaccine dose | Yes | |
Primary | Occurrence of serious adverse events (SAEs) | Throughout the entire study period | Yes | |
Primary | N antibody titers to each DEN serotype | At month 7 in unprimed subjects | No | |
Secondary | Occurence of suspected and laboratory confirmed dengue | Throughout the entire study period | Yes | |
Secondary | N antibody titer above the assay cut off to each DEN serotype | At months 0, 3, 6, and 7 | No | |
Secondary | N antibody titer above the assay cut-off to all dengue serotypes | At months 0, 3, 6, and 7 | No | |
Secondary | N sero-response to each DEN serotype | At months 0, 3, 6, and 7 | No | |
Secondary | N antibody titer to each DEN serotype | At months 0, 3, 6, and 7 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04514107 -
A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)
|
N/A | |
Completed |
NCT00788151 -
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
|
Phase 2 | |
Completed |
NCT02510638 -
The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia
|
N/A | |
Completed |
NCT01666652 -
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
|
Phase 1 | |
Completed |
NCT01477671 -
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
|
N/A | |
Completed |
NCT01443247 -
Role of Andi-d in Dengue Fever: a Pilot Study
|
N/A | |
Completed |
NCT00831012 -
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults
|
Phase 1 | |
Completed |
NCT00089908 -
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults
|
Phase 1 | |
Completed |
NCT01983553 -
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
|
||
Completed |
NCT01134263 -
Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia
|
Phase 3 | |
Completed |
NCT02741128 -
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
|
Phase 2 | |
Completed |
NCT03620487 -
Detection of Dengue Virus in Plasma of Patients in Nepal
|
||
Recruiting |
NCT02608047 -
Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou
|
N/A | |
Completed |
NCT02510690 -
Factors Associated With Poor Dengue Outcomes in Malaysia
|
N/A | |
Completed |
NCT01550016 -
International Research Consortium on Dengue Risk Assessment, Management, and Surveillance
|
N/A | |
Completed |
NCT01421732 -
Laboratory Diagnosis and Prognosis of Severe Dengue
|
N/A | |
Completed |
NCT00993447 -
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
|
Phase 2 | |
Completed |
NCT01224639 -
Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever
|
Phase 1 | |
Completed |
NCT01943825 -
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
|
Phase 2 | |
Active, not recruiting |
NCT03465254 -
Dengue Serostatus Study in the Philippines
|